Mini-Plenary Sessions

Wednesday, September 29, 2010
9:00 a.m. - 12:00 p.m.

Chemicals Energy Environment & Materials
Making Green Deals Green
Intermediate
This mini-plenary will include speakers representing diverse entities (gov/big co/small co/university/vc) in the cleantech, and particularly renewable energy space and intends to cover hot topics 1 and 2.  We have identified a list of candidate presenters (who have either volunteered or have been volunteered to present) from these entities, including international candidates.  The panelists are to discuss actual deals they have been involved in in the cleantech/renewables space and specifically what elements of the deal led to their success, or what went wrong with the deals and the lessons learned.  The government and VC reps will also discuss what consitutes a 'good deal' that leads to investment support.  And the government rep may further discuss how administrative changes such as (Renewable Fuel Standard) RFS2 or the accelerated patent prosecution program for green technologies might impact deals.  The MP will be interactive in format and encourage audience participation and ?s.

Chris Noble, Technology Licensing Officer, MIT
Casey Porto, Sr. Vice President, Commercialization & Deployment, National Renewable Energy Laboratory
Aaron Schuchart, Vice President, Business Development, Mendel Biotechnology, Inc.
Edna Vassilovski, Member, Stoel Rives LLP
Brandon Williams, Managing Director, IgniteIP, LLC

Consumer Products
The Importance of Brand Building
Novice
The format will be a panel discussion on successful and unsuccessful recent deals. The specific deals discussed will be the CP sector Deals of Distinction and other notable deals. Discussion will be very interactive, with much solicitation of audience perspective.

Moderator: Rimma Driscoll, Global Business Development, Procter & Gamble Company
Veronica Becerril, Consumer Market Knowledge, Procter & Gamble Co
Tim Brown, Senior VP and General Manager, US,  Mead Johnson Nutrition
Steve Wasik, Former CEO of SIGG; Senior Consultant, Riverside Group

High Technology
Google Book Search Settlement Agreement
Intermediate
The Google Book Search settlement agreement seeks to end the litigation between authors, publishers and Google by establishing of a complex new business arrangement that develops revenue models to compensate authors and publishers for the use of their copyrighted books through the Google Books Library Project. Under the proposed agreement, Google would pay out $125 million: $45 million to rightsholders whose copyrights had allegedly been infringed; $15.5 million to the publishers' legal fees; $30 million to the authors' lawyers; and $34.5 million toward the funding of a new entity provisionally called the Book Rights Registry, a form of copyright collective that would collect revenues from Google and that would dispense these revenues to the rightsholders. In exchange, Google would be released from liability for its book digitization.

Moderator: Michael Plonka
Allan Adler, Vice President for Legal & Government Affairs, Association of American Publishers, Inc.
Jonathan Band, Partner, Jonathan Band PLLC, Technology Law and Policy
Michael Graham, Partner, Marshall, Gerstein & Borun LLP

Industry-University-Government Interface
The License That Helped Transform A Global Health Crisis:  Celebrating the 25th Anniversary of the NIH / Abbott HIV Test Kit Agreement
Intermediate
Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV. It seems unbelievable today, but twenty-five years ago, this was the reality as the world struggled to keep the deadly virus out of the blood supply.  In 1985, an estimated one in 100 blood transfusions was infected with the HIV virus in some United States cities. Twenty-five years later — thanks to the innovative development of critical diagnostic tests that can identify HIV in the blood — this risk is now minimal and millions of patients are safely given blood transfusions each year.

The basis of this health care success story in the United States has been HIV diagnostic products developed and sold by Abbott Laboratories that are based on intellectual property licensed by the U.S. National Institutes of Health (NIH).  This ever-evolving license agreement, now also in its 25th year, has been key in bringing many new and innovative HIV testing prioducts to the market.

Guy Chambers, Partner, Duane Morris LLP
Steven Ferguson, Deputy Director, Licensing & Entrepreneurship, NIH Office of Technology Transfer
George Keller, Senior Expert, Monitoring & Enforcement, NIH Office of Technology Transfer 
Andrew Schapals, Senior Licensing Manager, Abbott Laboratories, Inc.
Norman Wald, Director, Global Scientific Affairs, Abbott Laboratories

Life Sciences
Part 1: Do You Know What's Happening in Your Markets?  Global BioPharmaceutical Royalty Rates & Deal Terms from the 2009 Global Survey by LES USA/Canada and LESI
Intermediate
Many sources of information on biopharmaceutical royalty rates and deal terms rely on Freedom of Information (FOI) sources from public companies in the United States, which only represent "material" deals that are generally more than five years old, or rely on press releases or public announcements which are often positioned for maximum publicity or promotional impact(i.e. the hyperbole of "BIO Bucks").

The Life Sciences Sectors of LES USA/Canada and LESI have partnered to conduct a landmark GLOBAL survey of royalty rates and deal terms for deals conducted in the past two years (2008, 2009).

The results represent deals submitted by over 200 companies with approximately one-half the deals submitted by companies outside the USA and Canada.

This Landmark Global Survey is a first of its' kind for the biopharmaceutical industry.

Jim McCarthy, Senior Vice President, Corporate Development, EGEN, Inc.
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance
Jeff Snell, Principal, Charles River Associates
Deni Zodda, Principal, Medignostica LLC

Part 2: Game Theory Applications to BioPharma Deal Negotiations
Intermediate
Ratchet Up Your Game For a Win-Win Outcomes in BioPharma Deal Negotiations. Game theory is a platform for providing important insights for consideration in negotiating deals--especially for deals between asymmetrical organizations from the perspective of size, pipeline and resources. This highly interactive workshop will combine the expertise of a Negotiating guru with a doctorate in financial economics and game theory with biopharma business development executives to examine deal strategies through the lens of game theory. This workshop will highlight a way of bringing competition and cooperation together when negotiating increasingly complex biopharma deal structures. Having the opportunity to look at all of our traditional options through the lens of game theory strategies will stimulate our thinking from multiple perspectives as we approach business development deals.

Bill Killian, Senior Director, Corporate Licensing and Acquisitions, Abbott Laboratories
Jeremy Middleton, Vice President, Corporate Development, Elusys Therapeutics
Ruth Plager, President & Chairman, ZenithBIO LLC
Mohan Rao, Managing Director, NavigantEconomics
Ramani Varanasi, Vice President, Business Development, RXi Pharmaceuticals